Beam Therapeutics Inc.

For the period ended Sep 30, 2026. Filed Nov 3, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 3, 2026

BEAM$25.15-6.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Other Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
License and collaboration revenue	$307	$9,698	$32,535	$25,634
Operating expenses:
Research and development	110,110	109,769	309,730	310,343
General and administrative	31,519	26,740	97,895	81,539
Total operating expenses	141,629	136,509	407,625	391,882
Loss from operations	(141,322)	(126,811)	(375,090)	(366,248)
Other income (expense):
Change in fair value of derivative liabilities	4,700	(2,600)	3,000	1,900
Change in fair value of non-controlling equity investments	(1,021)	4,937	(667)	7,271
Change in fair value of contingent consideration liabilities	(2,856)	1,000	(2,547)	945
Gain on sale of equity method investment	—	—	455	—
Interest and other income (expense), net	6,094	10,903	23,448	33,093
Total other income (expense)	6,917	14,240	23,689	43,209
Net loss	$(134,405)	$(112,571)	$(351,401)	$(323,039)
Unrealized gain (loss) on marketable securities	(1,245)	780	(4,545)	111
Comprehensive loss	$(135,650)	$(111,791)	$(355,946)	$(322,928)
Net loss per common share, basic and diluted	$(1.28)	$(1.10)	$(3.38)	$(3.31)
Weighted-average common shares outstanding, basic and diluted	104,698,517	102,570,801	104,100,991	97,567,229

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.